There has got to be a consideration about the buy-out premium on botanix x sofdra - people in the forum are talking about 18-24 months for us to really see what we actually have with sofdra, medtech/pharma co are decades past doing their own R&D and are happy to pay a short-term premium on pre-rev/very-early rev (bot) companies. The question is; who will buy it? I agree with others regarding a 'buy' sentiment; $70M in the kitty will let the team do their thing and allow them adequate runway to shop around for buyout partners. Without the CR, it'd be a different story.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $573.5M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.3¢ | 28.5¢ | $751.7K | 2.553M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 363281 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 205211 | 13 |
View Market Depth
| Last trade - 11.31am 18/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |